Hinweis-Modus ist eingeschaltet Ausschalten
Für eine schnelle Bewegung zwischen den Elementen

Unternehmen: Regeneron
LEI 549300RCBFWIRX3HYQ56

Firmenname
Regeneron Pharmaceuticals Inc
Name des Landes
Vereinigte Staaten
Eintragungsland
Vereinigte Staaten
Branche
Pharmazeutische Zubereitung und Biotechnologie
Anleihenschuld
2.000 Mio. USD

Entdecken Sie die umfangreichste Datenbank

800 000

Anleihen weltweit

Über 400

Kursquellen

80 000

Aktien

9 000

ETF

Verwalten Sie Ihr Portfolio auf effizienteste Weise
Bond-Screener
Watchlist
Excel-Add-In
Zugang erhalten

Letzte Daten zum

Kurse

Anfrage wurde gesendet
Zugang verboten
Anfrage senden
Die von Informationsanbietern bereitgestellten Kurse haben indikativen Charakter

Profil

Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.

Auszeichnungen

Nachrichten

02/02/2024 Regeneron Posts Strong Q4 Earnings
02/02/2024 Regeneron: Results Of Operations And Financial Condition, Financial Statements And Exhibits
31/01/2024 Regeneron: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
08/01/2024 Regeneron: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
07/01/2024 Moody's Investors Service upgrades LT- local currency credit rating of Regeneron to "Baa1" from "Baa2"; outlook stable
Alle Nachrichten des Unternehmens

Dokumente

IFRS/US GAAP Finanzberichte

2024
I Q Eng.
2023
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2022
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2021
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2020
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2019
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2018
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2017
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2016
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2015
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2014
IV Q Eng.
Alle anzeigen Verstecken
Sie müssen sich einloggen
Sie benötigen einen Zugang

Aktien

Letzte Anleihen

Alle anzeigen

Anleihenschuld nach Währung

Alle anzeigen Verstecken

Codes

  • LEI
    549300RCBFWIRX3HYQ56
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0000872589
  • EIN
    13-3444607

Kredit- und ESG-Ratings

Makroökonomie

Sie müssen sich registrieren , um Zugriff zu erhalten.